a The Influenza Center.
b Emergency Care Clinic.
Hum Vaccin Immunother. 2018 Mar 4;14(3):571-578. doi: 10.1080/21645515.2017.1377376. Epub 2018 Jan 3.
Since 2003 (US) and 2012 (Europe) the live attenuated influenza vaccine (LAIV) has been used as an alternative to the traditional inactivated influenza vaccines (IIV). The immune responses elicted by LAIV mimic natural infection and have been found to provide broader clinical protection in children compared to the IIVs. However, our knowledge of the detailed immunological mechanisims induced by LAIV remain to be fully elucidated, and despite 14 years on the global market, there exists no correlate of protection. Recently, matters are further complicated by differing efficacy data from the US and Europe which are not understood. Better understanding of the immune responses after LAIV may aid in achieving the ultimate goal of a future "universal influenza vaccine". In this review we aim to cover the current understanding of the immune responses induced after LAIV.
自 2003 年（美国）和 2012 年（欧洲）以来，减毒活流感疫苗（LAIV）已被用作传统灭活流感疫苗（IIV）的替代品。LAIV 引发的免疫反应模拟了自然感染，并且已被发现与 IIV 相比，在儿童中提供更广泛的临床保护。然而，我们对 LAIV 诱导的详细免疫机制的了解仍有待充分阐明，尽管它已经在全球市场上存在了 14 年，但仍没有保护相关物。最近，美国和欧洲的数据显示出不同的疗效，这让人感到困惑，这些情况进一步使事情变得复杂。对 LAIV 后免疫反应的更好理解可能有助于实现未来“通用流感疫苗”的最终目标。在这篇综述中，我们旨在涵盖对 LAIV 后诱导的免疫反应的现有理解。
